ImmuneOnco Biopharmaceuticals (Shanghai)'s Cancer Drug Gets NMPA`s Nod for Clinical Trial

MT Newswires Live
06 Mar

ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) said it received approval from China's National Medical Products Administration (NMPA) for a clinical trial of IMM01 (Timdarpacept), its cancer drug, in combination with IMM2510 (palverafusp α), according to a Thursday filing with the Hong Kong bourse.

The drug is used in combination with palverafusp α for the treatment of advanced malignant tumors, with or without chemotherapy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10